Program Schedule

602
Elevation in Liver Transaminase (ALT-flares) in Transplant (TX) Recipients: Risk factors and Consequences

Session: Oral Abstract Session: Hot Topics in Transplant ID
Thursday, October 9, 2014: 8:45 AM
Room: The Pennsylvania Convention Center: 105-AB

Background: ALT-flares are frequently observed in TX recipients, but the underlying reason is only known for a fraction. At our hospital, performing a large number of solid organ (SOT) and human stem cell TX's (HSCT), we initiated a program aimed at improving our understanding of the clinical implication from liver injury during post-TX follow-up (FU). Here we report on the incidence and risk factors for ALT flares, and the short- and long-term association with mortality.

Methods: Analysis included 1002 SOT (kidney (n=328), liver (170), lung (120), and heart (47)) and HSCT (337) recipients at our hospital, consecutive transplanted between Sept/09-July/13, and with prospective FU ≤ Oct/13. ALT-flares (>1.25xULN) were classified according to grade (NIH) and recognized cause (patient notes review). Poisson regression was used to determine incidence rate ratios (IRRs) of flares and death; generalized estimated equations allowed for repeated flares within individuals.  Number and type of flare was included in models as time-updated variables.

Results: 501 of 1002 (50%) patients experienced a total of 1197 ALT-flares (46% had 1, 23% 2, and 31% >2 flares) during 1937 person years of FU (incidence 0.62 (95% CI 0.58-0.65)/PYFU). The reasons for the ALT flare was often unknown (50%), due to infections (12%), drug-induced (DILI-11%) or other reasons, and most were grade 2-3 (16% grade 4). Incidence of flares was elevated for all types of TX compared with kidney TX, was high in first 4-12 weeks postTX and plateaued thereafter for all except liver SOT (fig). During FU, 152 recipients died, and the adjusted IRR of death associated with experiencing 1, 2, or >2 (versus 0) ALT-flares were 1.1 (0.6-2.0), 2.1 (1.1-3.7), and 5.1 (3.2-8.1); the excess risk with >2 ALT flares persisted when lagging time between ALT flare and death by up to 6 months, for all types of ALT flares (p<0.05)(except DILI-associated), accounting for competing risk or excluding liver TX patients.

Conclusion: ALT flares occur frequently in the first 3 months after all types of TX, often remains unexplained, but if occurring several times is associated with excess risk of death 6 months thereafter. A better understanding of currently unrecognized factor contributing to ALT flares in this setting (e.g. HEV) is warranted.

Adjusted incidence rate ratio of flare after tx.JPG

Louise Lundgren, Pregraduate Research Fellow1, Caspar Da Cunha-Bang, MD PhD2, Amanda Mocroft, Professor3, Jens Lundgren, MD, D.M.Sc., Professor4, Finn Gustafsson, MD, Phd5, Martin Iversen, MD, D.M.Sc.5, Nikolai Kirkby, MSc Phd6, Allan Rasmussen, MD7, Søren Schwartz Sørensen, MD, D.M.Sc.8, Lars Vindeløv, MD, D.M.Sc1, Henrik Sengeløv, MD, D.M.Sc.9 and MATCH Programme Study Group, (1)Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, (2)Department of Infectious and Rheumatology, Chip, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, (3)Dept Infection and Population Health, HIV Epidemiology and Biostatistics Unit, University College London, London, England, (4)Department of Infectious Diseases and Rheumatology, Chip, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, (5)Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, (6)Department of Clinical Microbiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, (7)Department of Abdominal Surgery, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, (8)Department of Nephrology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, (9)Hematopoietic Stem Cell Transplant Unit, University hospital, Rigshospitalet, Copenhagen, Denmark

Disclosures:

L. Lundgren, None

C. Da Cunha-Bang, None

A. Mocroft, None

J. Lundgren, None

F. Gustafsson, None

M. Iversen, None

N. Kirkby, None

A. Rasmussen, None

S. Schwartz Sørensen, None

L. Vindeløv, None

H. Sengeløv, None

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek